Precision Biosciences (DTIL) Asset Utilization Ratio (2019 - 2026)
Precision Biosciences (DTIL) posted quarterly Asset Utilization Ratio of 0.3 for Q1 2026, down 22.95% year-over-year from 0.39 in Q1 2025, and up 9.33% quarter-over-quarter from 0.28 in Q4 2025.
Precision Biosciences (DTIL) Asset Utilization Ratio (2019 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Asset Utilization Ratio for 8 consecutive years, with 0.3 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Utilization Ratio fell 22.95% year-over-year to 0.3; the TTM figure through Mar 2026 stood at 0.3 (down 22.95% YoY), while the FY2025 annual figure was 0.24, down 49.2% from the prior year.
- Asset Utilization Ratio improved to 0.3 in Q1 2026 per DTIL's latest filing, from 0.28 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.52 in Q1 2022 and bottomed at 0.01 in Q3 2025.
- Historically, Asset Utilization Ratio has averaged 0.27 across 5 years, with a median of 0.3 in 2023.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio jumped 312.5% — and 2025, when it slumped 98.54%.
- Precision Biosciences' Asset Utilization Ratio stood at 0.1 in 2022, then soared by 205.43% to 0.3 in 2023, then surged by 57.76% to 0.47 in 2024, then sank by 41.73% to 0.28 in 2025, then gained by 9.33% to 0.3 in 2026.
- Business Quant data shows DTIL's Asset Utilization Ratio at 0.3 in Q1 2026, 0.28 in Q4 2025, and 0.01 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | 0.33 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.33 |
| Mar 31, 2026 | 0.30 |
| Dec 31, 2025 | 0.28 |
| Sep 30, 2025 | 0.01 |
| Jun 30, 2025 | 0.01 |
| Mar 31, 2025 | 0.39 |
| Dec 31, 2024 | 0.47 |
| Sep 30, 2024 | 0.47 |
| Jun 30, 2024 | 0.50 |
| Mar 31, 2024 | 0.33 |
| Dec 31, 2023 | 0.30 |
| Sep 30, 2023 | 0.30 |
| Jun 30, 2023 | 0.24 |
| Mar 31, 2023 | 0.14 |
| Dec 31, 2022 | 0.10 |
| Sep 30, 2022 | 0.07 |
| Jun 30, 2022 | 0.16 |
| Mar 31, 2022 | 0.52 |
| Dec 31, 2021 | 0.53 |
| Sep 30, 2021 | 0.52 |